The conventional clinical approach to breast cancer diagnosis, treatment patterns, and prognosis takes into account age, menopausal status, tumor (T)/node (N)/metastasis (M) classification, histological grade, tumor size, axillary lymph node status, Ki67 expression, hormone receptors, and human epidermal growth factor receptor 2 (HER2) status [8]. This evidence concerns the gene ERBB2 and breast carcinoma.